Core Viewpoint - Yao Jinbo, the founder of 58.com, has acquired a 23% stake in Yiming Pharmaceutical for 662 million yuan, becoming the actual controller of the company, marking his entry into the pharmaceutical industry [1][4]. Group 1: Investment Details - The share transfer agreement was signed between Beijing Fuhao and the current controlling shareholder Gao Fan, with a price of 15.10 yuan per share, totaling 662 million yuan [4]. - Following the transaction, the controlling shareholder of Yiming Pharmaceutical will change from Gao Fan to Beijing Fuhao, with Yao Jinbo becoming the actual controller [1][4]. - Gao Fan has committed that Yiming Pharmaceutical's net profit will not be less than 30 million yuan annually for the next three years, and the revenue will not be less than 600 million yuan each year [4]. Group 2: Company Performance - Yiming Pharmaceutical focuses on the treatment of chronic diseases such as diabetes and cardiovascular diseases, with key products that are included in the national medical insurance directory [5]. - The company reported a revenue of 650 million yuan, a decrease of 2.27% year-on-year, while the net profit attributable to shareholders was 45.93 million yuan, an increase of 198.5% year-on-year [5]. - The growth in profit is attributed to the absence of goodwill impairment losses in 2024, as well as the performance increase of self-produced products [5][6]. Group 3: Market Context and Strategy - Analysts suggest that Yao Jinbo's investment in the pharmaceutical sector is driven by the industry's high growth potential, as his previous investments were primarily in stable sectors [2][8]. - Yao Jinbo's investment strategy has shifted towards high-growth industries, indicating a potential for further involvement in the operations of Yiming Pharmaceutical [8].

Investment Rating - The report indicates a positive sentiment towards the company following the acquisition by Yao Jinbo, founder of 58.com, suggesting a potential for value re-evaluation in the market [2][3]. Core Insights - The acquisition price of 15.10 CNY per share represents a 24% premium over the last closing price and a 30% premium over the 20-day average prior to suspension, indicating strong confidence from the new management [2]. - Despite the acquisition, the company's fundamentals show stagnation, with revenues projected to grow only slightly from 600 million CNY in 2020 to 650 million CNY in 2024, and a decline of 7.4% in Q1 2025 [3][5]. - The company is characterized as a "clean shell," with a strong cash position of 320 million CNY, receivables of 170 million CNY, and total liabilities under 300 million CNY, which includes only 50 million CNY in interest-bearing debt [8][9]. Summary by Sections - **Company Overview**: Yao Jinbo's acquisition marks the first A-share listed company under his control, transitioning Easy Ming Pharmaceutical from a lesser-known entity to a more prominent player in the market [2]. - **Financial Performance**: The company has maintained a stable net profit of around 30-40 million CNY, with R&D expenses of over 15 million CNY in 2024, which raises concerns about growth potential in a competitive industry [5][11]. - **Future Expectations**: The previous controlling shareholder's performance commitments for 2025-2027 include revenue not less than 600 million CNY and net profit not less than 30 million CNY, which sets a baseline for future performance expectations under the new management [11].

Core Viewpoint - The acquisition of shares in Yiming Pharmaceutical by Beijing Fuhai marks a significant change in control, with the new actual controller being Yao Jinbo, founder of 58.com, aiming to enhance the company's business development and asset quality [1][3]. Group 1: Share Transfer Details - Beijing Fuhai plans to acquire 43,855,883 shares of Yiming Pharmaceutical from Gao Fan at a price of 15.10 yuan per share, totaling 662 million yuan, which represents 23.00% of the company's total shares [1]. - Following the completion of this transaction, the controlling shareholder will shift from Gao Fan to Beijing Fuhai, with Yao Jinbo becoming the new actual controller [1]. Group 2: Company Performance - Yiming Pharmaceutical has experienced a decline in revenue over the past two years, with projected revenues of 667 million yuan and 652 million yuan for 2023 and 2024, reflecting year-on-year decreases of 22.14% and 2.27% respectively [2]. - The net profit attributable to the parent company for 2023 and 2024 is expected to be 15.39 million yuan and 45.93 million yuan, showing a significant year-on-year change of -65.14% and 198.50% respectively [2]. - In Q1 2025, Yiming Pharmaceutical reported a revenue of 149 million yuan, down 7.41% year-on-year, and a net profit of 18.79 million yuan, down 32.64% year-on-year [2]. Group 3: Performance Commitment - Gao Fan has made performance commitments for Yiming Pharmaceutical, ensuring that the company achieves a minimum revenue of 600 million yuan for each fiscal year from 2025 to 2027, and a net profit of no less than 30 million yuan [2]. - For 2028, the commitments include maintaining positive figures for net profit, total assets, and net assets, along with compliance with specific regulations [2]. Group 4: Market Reaction - Following the announcement of the share transfer, Yiming Pharmaceutical's stock was suspended from trading on May 27, 2025, and upon resuming trading on June 4, it opened at a limit-up price of 13.40 yuan per share, reflecting a 10.02% increase [3].

西藏易明西雅医药科技股份有限公司（以下简称"公司"）全资子公司四 川维奥制药有限公司（以下简称"维奥制药"）近日收到政府补助485.30万 元，占公司2024年度经审计归属于上市公司股东净利润的10.57%。 上述政府补助与公司日常经营活动相关，不具有可持续性。 二、补助的类型及其对公司的影响 根据《企业会计准则第16号-政府补助》的规定，与资产相关的政府补助， 是指企业取得的、用于购建或以其他方式形成长期资产的政府补助；与收益相关 的政府补助，是指除与资产相关的政府补助之外的政府补助。 公司本次获得的政府补助属于与收益相关的政府补助。 证券代码：002826 证券简称：易明医药 公告编号：2025-039 西藏易明西雅医药科技股份有限公司 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有 虚假记载、误导性陈述或重大遗漏。 一、获取补助的基本情况 上述政府补助预计将增加公司2025年度利润总额485.30万元。 上述数据未经审计，最终的会计处理及对公司损益的影响以年度审计机构 审计结果为准，敬请广大投资者注意投资风险。 三、备查文件 特此公告。 西藏易明西雅医药科技股份有限公司 董事会 二〇二五 ...

Core Viewpoint - The control of Yiming Pharmaceutical (002826.SZ) is changing hands from its founder Gao Fan to Beijing Fuhai, with the new actual controller being Yao Jinbo, marking a significant shift in the company's ownership structure [2][3][8]. Group 1: Ownership Change - Gao Fan signed a share transfer agreement to sell 23% of his shares to Beijing Fuhai at a price of 15.10 yuan per share, totaling 662 million yuan [2]. - Following the announcement, Yiming Pharmaceutical's stock resumed trading and hit the daily limit up, opening at 13.40 yuan per share [2]. - The new controller, Yao Jinbo, is also the chairman and CEO of 58.com and holds a significant stake in Kuaigou Dache [3][4]. Group 2: Financial Commitments - The share transfer agreement includes performance commitments, with a revenue target of no less than 600 million yuan annually from 2025 to 2027, and a net profit target of at least 30 million yuan for the same period [8]. - If performance targets are not met, Gao Fan will provide compensation based on specific conditions outlined in the agreement [8]. Group 3: Company Performance - Yiming Pharmaceutical's revenue for 2022, 2023, and projected 2024 are 857 million yuan, 667 million yuan, and 652 million yuan respectively, with net profits of 44 million yuan, 15 million yuan, and 46 million yuan [9]. - The company has shown a decline in revenue and profitability, with a significant reliance on its diabetes drug, Miglitol, which generated 474 million yuan in 2024, accounting for 72.72% of total revenue [9]. - The cardiovascular product, Guo Loupian injection, has seen a drastic revenue drop of 55.61% in 2024, leading to the termination of its partnership with Shanghai Pharmaceutical Group [9][10].

证券代码：002826 证券简称：易明医药 公告编号：2025-039 西藏易明西雅医药科技股份有限公司 关于子公司获得政府补助的公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有 虚假记载、误导性陈述或重大遗漏。 一、获取补助的基本情况 西藏易明西雅医药科技股份有限公司（以下简称"公司"）全资子公司四 川维奥制药有限公司（以下简称"维奥制药"）近日收到政府补助485.30万 元，占公司2024年度经审计归属于上市公司股东净利润的10.57%。 上述政府补助与公司日常经营活动相关，不具有可持续性。 二、补助的类型及其对公司的影响 1、补助的类型 根据《企业会计准则第16号-政府补助》的规定，与资产相关的政府补助， 是指企业取得的、用于购建或以其他方式形成长期资产的政府补助；与收益相关 的政府补助，是指除与资产相关的政府补助之外的政府补助。 2、补助的确认、计量 根据《企业会计准则第16号——政府补助》的规定，公司收到与收益相关 的政府补助时，与企业日常活动相关的政府补助，按照经济业务实质，计入其 他收益或冲减相关成本费用，与企业日常活动无关的政府补助，计入营业外收 入。 本次公司收到485. ...

Group 1 - The core point of the news is the acquisition of control over Yiming Pharmaceutical by Yao Jinbo, founder of 58.com, for 662 million yuan, which represents a 24% premium over the previous closing price [1][2] - Yao Jinbo's company, Beijing Fuhao, will acquire 23% of Yiming Pharmaceutical's shares at a price of 15.10 yuan per share, changing the actual controller from Gao Fan to Yao Jinbo [2][3] - Yiming Pharmaceutical has faced significant performance challenges, with a 22.14% decline in revenue and a 65.14% drop in net profit in 2023, indicating reliance on a single product, Miglitol tablets, which accounted for 72.72% of revenue [4][5] Group 2 - The transaction includes a performance guarantee where Yiming Pharmaceutical must achieve audited annual revenues of no less than 600 million yuan and net profits of no less than 30 million yuan for the years 2025, 2026, and 2027 [3] - Other companies, such as Feiling'er, are also undergoing control changes, with significant stakes being transferred to various buyers, including state-owned enterprises and private equity firms [6][8] - The trend of control changes among listed companies has been notable this year, with various combinations of buyers, including industrial capital and state-owned entities [6][7]

Core Viewpoint - The acquisition of Yiming Pharmaceutical by Beijing Fuhao has led to a significant increase in the company's stock price, with a closing price of 13.4 yuan per share, marking a 10.02% rise and a total market value of 2.555 billion yuan [2]. Group 1: Acquisition Details - Beijing Fuhao signed a share transfer agreement with the controlling shareholder Gao Fan to acquire 43.8559 million shares of Yiming Pharmaceutical, representing 23% of the total shares, at a price of 15.1 yuan per share, totaling 662 million yuan [2]. - The acquisition price reflects a premium of 23.97% over the closing price of 12.18 yuan per share on the trading day prior to the agreement [2]. - Beijing Fuhao was established specifically for this transaction and has not yet commenced actual business operations [2]. Group 2: New Leadership - The new controlling shareholder, Yao Jinbo, is the founder of 58.com and has significant experience in various sectors, including life services, finance, and advanced manufacturing [4][5]. - The change in control is expected to bring new management ideas, funding support, and opportunities in new markets for Yiming Pharmaceutical [6]. Group 3: Performance Commitments - The share transfer agreement includes performance commitments, with the seller promising that the existing business will achieve audited net profits of no less than 30 million yuan from 2025 to 2027 [8]. - Yiming Pharmaceutical's main revenue sources include diabetes and cardiovascular drugs, with a significant contribution expected from the α-glucosidase inhibitor Miglitol tablets [8]. - The company reported a decline in revenue and net profit in the first quarter of the year, with a total revenue of approximately 149 million yuan, down 7.41% year-on-year, and a net profit of approximately 18.79 million yuan, down 32.64% year-on-year [9].

截至收盘，上证指数报收3376.20点，上涨0.42%；深证成指收于10144.58点，上涨0.87%；创业板指上 涨1.11%；科创50指数上涨0.45%。 不含当日上市新股，今日可交易A股中，上涨个股有3964只，占比73.60%，下跌个股有1238只，平盘个 股184只。其中，收盘股价涨停的有87只，跌停股有2只。 证券时报·数据宝统计显示，涨停个股中，主板有81只，创业板6只。以所属行业来看，上榜个股居前的 行业有轻工制造、医药生物、电力设备行业，上榜个股分别有10只、6只、6只。 涨停股中，*ST荣控、ST金鸿等16只股为ST股。连续涨停天数看，御银股份、ST联合等已连收5个涨停 板，连续涨停板数量最多。从收盘涨停板封单量来看，ST联合最受资金追捧，收盘涨停板封单有 3517.15万股，其次是中嘉博创、合兴股份等，涨停板封单分别有3353.60万股、2274.51万股。以封单金 额计算，合兴股份、易明医药、ST联合等涨停板封单资金较多，分别有5.50亿元、2.68亿元、2.02亿 元。（数据宝） 两市涨停股一览 | 代码 | 简称 | 收盘价（元） | 换手率（%） | 涨停板封单（万股） | 封单 ...

易明医药工作人员在接受南财快讯记者以投资者身份采访时表示，北京福好实际控制人"姚劲波"确为58同城的姚劲波。 至于姚劲波入股的目的和接下来有无资本运作计划，该人员表示，公司目前的业务不会变，姚劲波可能帮助公司（业务）赋能。 记者还多次致电北京福好，语音显示为58同城客服电话，未获有效接通。 易明医药（002826.SZ）于4日复牌，开盘后一字涨停，报13.40元/股，总市值达25.55亿元。 消息面上，易明医药昨晚发布公告称，公司控股股东、实际控制人高帆与北京福好企业管理合伙企业（有限合伙）（简称"北京福好"）签署了《股份转让 协议》，高帆拟将其持有的23%公司股份转让给北京福好，转让价格为15.10元/股，总转让价款为6.62亿元。 本次权益变动实施完成后，上市公司控股股东将由高帆变更为北京福好，实际控制人将由高帆变更为姚劲波。 公告显示，北京福好实际控制人为姚劲波，北京福好两个股东之一的北京福雅企业管理有限责任公司股东为姚劲波和戴科英，戴科英为姚劲波配偶。 具体来看，转让方承诺：目标公司现有业务板块在业绩承诺期内2025年度至2027年度实现的扣非归母净利润均不低于3000万元（"承诺利润"）；2028年 ...